Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
Ruth Link‐Gelles, Elizabeth Rowley, Malini B. DeSilva, Kristin Dascomb, Stephanie A. Irving, Nicola P. Klein, Shaun J. Grannis, Toan C. Ong, Zachary A. Weber, Katherine E. Fleming-Dutra, Charlene McEvoy, Omobosola Akinsete, Daniel Bride, Tamara Sheffield, Allison L. Naleway, Ousseny Zerbo, Bruce Fireman, John Hansen, Kristin Goddard, Brian E. Dixon, Colin Rogerson, William F. Fadel, Thomas J. Duszynski, Suchitra Rao, Michelle A. Barron, Sarah E. Reese, Sarah W. Ball, Margaret M. Dunne, Karthik Natarajan, Erica Okwuazi, Ami B. Shah, Ryan E. Wiegand, Mark W. Tenforde, Amanda B. Payne
Abstract
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged ≥18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged ≥6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses ≥2 months after the last recommended COVID-19 vaccine.